Search research articles
Contact Us
Filters
Showing results (31-40 of 265) with videos related to
Page
of 27
Sort By:
Journal of Cancer Education : the Official Journal of the American Association for Cancer Education
|
June 16, 2009
If you hold it off-hours, will they come? Results from a feasibility project intended to stimulate interest in the physician-investigator career path among medical oncology trainees
Tow S Tan, Tamana Walia, Eva Galanis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 10, 2010
Oncophenotypic review and clinical correlates of phosphatase and tensin homolog on chromosome 10 hamartoma tumor syndrome
Mrinal M Patnaik, Sania S Raza, Sherezade Khambatta, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences
|
April 2, 2023
Development and validation of a liquid chromatography-mass spectrometry assay for quantification of Z- and E- isomers of endoxifen and its metabolites in plasma from women with estrogen receptor positive breast cancer
Sarah A Buhrow, Emily J Koubek, Matthew P Goetz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 11, 2025
Endocrine Therapy Omission in Estrogen Receptor-Low (1%-10%) Early-Stage Breast Cancer
Grace M Choong, Tanya L Hoskin, Judy C Boughey, et al.
Annals of Surgical Oncology
|
January 6, 2017
Has the Time Come to Stop Surgical Staging of the Axilla for All Women Age 70 Years or Older with Hormone Receptor-Positive Breast Cancer?
Judy C Boughey, Bruce G Haffty, Elizabeth B Habermann, et al.
Annals of Surgical Oncology
|
September 12, 2024
In-Breast Tumor Progression During Neoadjuvant Chemotherapy: Impact on and Factors Influencing Distant Recurrence-Free Survival
Kathryn M Eckert, Tanya L Hoskin, Carrie A Olson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 19, 2019
Tamoxifen Metabolism and Breast Cancer Recurrence: A Question Unanswered by CYPTAM
Matthew P Goetz, Vera J Suman, Yusuke Nakamura, et al.
Cancer Research
|
February 27, 2009
The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cells
Xianglin Wu, John R Hawse, Malayannan Subramaniam, et al.
Breast Cancer Research and Treatment
|
October 25, 2023
Nodal pCR and overall survival following neoadjuvant chemotherapy for node positive ER+/Her2- breast cancer
Dan Moldoveanu, Tanya L Hoskin, Courtney N Day, et al.
Annals of Surgical Oncology
|
July 17, 2023
Clinical Behavior, Management, and Treatment Response of Estrogen Receptor Low (1-10%) Breast Cancer
Dan Moldoveanu, Tanya L Hoskin, Courtney N Day, et al.
Page
of 27
Search research articles
Search
Showing results (31-40 of 265) with videos related to
Sort By:
Page
of 27
Journal of Cancer Education : the Official Journal of the American Association for Cancer Education
|
June 16, 2009
If you hold it off-hours, will they come? Results from a feasibility project intended to stimulate interest in the physician-investigator career path among medical oncology trainees
Tow S Tan, Tamana Walia, Eva Galanis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 10, 2010
Oncophenotypic review and clinical correlates of phosphatase and tensin homolog on chromosome 10 hamartoma tumor syndrome
Mrinal M Patnaik, Sania S Raza, Sherezade Khambatta, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences
|
April 2, 2023
Development and validation of a liquid chromatography-mass spectrometry assay for quantification of Z- and E- isomers of endoxifen and its metabolites in plasma from women with estrogen receptor positive breast cancer
Sarah A Buhrow, Emily J Koubek, Matthew P Goetz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 11, 2025
Endocrine Therapy Omission in Estrogen Receptor-Low (1%-10%) Early-Stage Breast Cancer
Grace M Choong, Tanya L Hoskin, Judy C Boughey, et al.
Annals of Surgical Oncology
|
January 6, 2017
Has the Time Come to Stop Surgical Staging of the Axilla for All Women Age 70 Years or Older with Hormone Receptor-Positive Breast Cancer?
Judy C Boughey, Bruce G Haffty, Elizabeth B Habermann, et al.
Annals of Surgical Oncology
|
September 12, 2024
In-Breast Tumor Progression During Neoadjuvant Chemotherapy: Impact on and Factors Influencing Distant Recurrence-Free Survival
Kathryn M Eckert, Tanya L Hoskin, Carrie A Olson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 19, 2019
Tamoxifen Metabolism and Breast Cancer Recurrence: A Question Unanswered by CYPTAM
Matthew P Goetz, Vera J Suman, Yusuke Nakamura, et al.
Cancer Research
|
February 27, 2009
The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cells
Xianglin Wu, John R Hawse, Malayannan Subramaniam, et al.
Breast Cancer Research and Treatment
|
October 25, 2023
Nodal pCR and overall survival following neoadjuvant chemotherapy for node positive ER+/Her2- breast cancer
Dan Moldoveanu, Tanya L Hoskin, Courtney N Day, et al.
Annals of Surgical Oncology
|
July 17, 2023
Clinical Behavior, Management, and Treatment Response of Estrogen Receptor Low (1-10%) Breast Cancer
Dan Moldoveanu, Tanya L Hoskin, Courtney N Day, et al.
Page
of 27